These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25013997)

  • 61. Efficacy and safety of individualized growth hormone treatment in adult Japanese patients with growth hormone deficiency.
    Chihara K; Kato Y; Shimatsu A; Tanaka T; Kohno H
    Growth Horm IGF Res; 2008 Oct; 18(5):394-403. PubMed ID: 18395480
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.
    Zdravkovic M; Søgaard B; Ynddal L; Christiansen T; Agersø H; Thomsen MS; Falch JE; Ilondo MM
    Growth Horm IGF Res; 2000 Aug; 10(4):193-8. PubMed ID: 11032702
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
    de Boer H; Blok GJ; Popp-Snijders C; Stuurman L; Baxter RC; van der Veen E
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration.
    Keller A; Wu Z; Kratzsch J; Keller E; Blum WF; Kniess A; Preiss R; Teichert J; Strasburger CJ; Bidlingmaier M
    Eur J Endocrinol; 2007 Jun; 156(6):647-53. PubMed ID: 17535864
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A low starting dose of genotropin in growth hormone-deficient adults.
    Janssen YJ; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 1997 Jan; 82(1):129-35. PubMed ID: 8989246
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
    Agersø H; Jensen LB; Elbrønd B; Rolan P; Zdravkovic M
    Diabetologia; 2002 Feb; 45(2):195-202. PubMed ID: 11935150
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
    J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.
    Cook DM; Biller BM; Vance ML; Hoffman AR; Phillips LS; Ford KM; Benziger DP; Illeperuma A; Blethen SL; Attie KM; Dao LN; Reimann JD; Fielder PJ
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4508-14. PubMed ID: 12364427
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
    Gill MS; Toogood AA; Jones J; Clayton PE; Shalet SM
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency.
    Khadilkar V; Radjuk KA; Bolshova E; Khadgawat R; El Kholy M; Desai M; Peterkova V; Mericq V; Kratzsch J; Siepl EC; Martin D; Lopez P; Ji HJ; Bae YJ; Lee JH; Saenger PH
    J Clin Endocrinol Metab; 2014 Jan; 99(1):126-32. PubMed ID: 24170106
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes.
    Nelson AE; Meinhardt U; Hansen JL; Walker IH; Stone G; Howe CJ; Leung KC; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2213-22. PubMed ID: 18381573
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men.
    de Boer H; Blok GJ; Voerman B; Derriks P; van der Veen E
    Int J Obes Relat Metab Disord; 1996 Jun; 20(6):580-7. PubMed ID: 8782736
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
    Juul RV; Rasmussen MH; Agersø H; Overgaard RV
    Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency.
    Cohen-Barak O; Sakov A; Rasamoelisolo M; Bassan M; Brown K; Mendzelevski B; Spiegelstein O
    Eur J Endocrinol; 2015 Nov; 173(5):541-51. PubMed ID: 26286586
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone.
    Hershkovitz O; Bar-Ilan A; Guy R; Felikman Y; Moschcovich L; Hwa V; Rosenfeld RG; Fima E; Hart G
    Mol Pharm; 2016 Feb; 13(2):631-9. PubMed ID: 26713839
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.
    Touraine P; D'Souza GA; Kourides I; Abs R; Barclay P; Xie R; Pico A; Torres-Vela E; Ekman B;
    Eur J Endocrinol; 2009 Oct; 161(4):533-40. PubMed ID: 19654233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.